75 related articles for article (PubMed ID: 1345113)
21. [Bactericide activity of sulbactam before bacteria belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex].
Villar HE; Laurino G; Hoffman M
Enferm Infecc Microbiol Clin; 1996 Nov; 14(9):524-7. PubMed ID: 9035707
[TBL] [Abstract][Full Text] [Related]
22. Identification of distinct ciprofloxacin susceptibility in Acinetobacter spp. by detection of the gyrA gene mutation using real-time PCR.
Sheng WH; Lin YC; Wang JT; Chen YC; Chang SC; Hsia KC; Wu RJ; Li SY
Mol Cell Probes; 2009; 23(3-4):154-6. PubMed ID: 19281841
[TBL] [Abstract][Full Text] [Related]
23. [Evolution of antimicrobial susceptibility of Acinetobacter baumannii clinical isolates].
López-Hernández S; Alarcón T; López-Brea M
Rev Esp Quimioter; 2000 Dec; 13(4):394-400. PubMed ID: 11498706
[TBL] [Abstract][Full Text] [Related]
24. Photoinactivation of Acinetobacter baumannii and Escherichia coli B by a cationic hydrophilic porphyrin at various light wavelengths.
Nitzan Y; Ashkenazi H
Curr Microbiol; 2001 Jun; 42(6):408-14. PubMed ID: 11381332
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
[TBL] [Abstract][Full Text] [Related]
26. Acinetobacter baumannii at a tertiary-care teaching hospital in Jerusalem, Israel.
Simhon A; Rahav G; Shazberg G; Block C; Bercovier H; Shapiro M
J Clin Microbiol; 2001 Jan; 39(1):389-91. PubMed ID: 11136809
[TBL] [Abstract][Full Text] [Related]
27. [In vitro antibacterial activity of piperacillin/quinolone combinations].
Soussy CJ; Leclercq R; Duval J
Pathol Biol (Paris); 1988 May; 36(5):357-60. PubMed ID: 3136421
[TBL] [Abstract][Full Text] [Related]
28. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting.
Gottesman BS; Carmeli Y; Shitrit P; Chowers M
Clin Infect Dis; 2009 Sep; 49(6):869-75. PubMed ID: 19686074
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
30. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
31. Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria.
Berlanga M; Montero MT; Hernández-Borrell J; Viñas M
Int J Antimicrob Agents; 2004 Jun; 23(6):627-30. PubMed ID: 15194135
[TBL] [Abstract][Full Text] [Related]
32. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
33. Optimization of the use of ciprofloxacin.
Aubert G; Carricajo A; Fonsale N; Vautrin AC
Pathol Biol (Paris); 2009 May; 57(3):236-9. PubMed ID: 18328635
[TBL] [Abstract][Full Text] [Related]
34. Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye.
Silva F; Lourenço O; Queiroz JA; Domingues FC
J Antibiot (Tokyo); 2011 Apr; 64(4):321-5. PubMed ID: 21326251
[TBL] [Abstract][Full Text] [Related]
35. Loss of ciprofloxacin's second killing action in Escherichia coli that have developed 4-quinolone resistance during therapy.
Lewin CS; Blakemore P; Drabu YJ; Smith JT
J Antimicrob Chemother; 1990 Oct; 26(4):594-6. PubMed ID: 2254228
[No Abstract] [Full Text] [Related]
36. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.
Zeiler HJ
Antimicrob Agents Chemother; 1985 Oct; 28(4):524-7. PubMed ID: 2934022
[TBL] [Abstract][Full Text] [Related]
37. [Effect of biologically active substances on Escherichia coli chloramphenicol acetyltransferase activity].
Solov'eva NN; Belousova II; Tereshin IM
Antibiotiki; 1979 Jun; 24(6):436-40. PubMed ID: 378112
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli.
Mascellino MT; Iona E; Iegri F; De Gregoris P; Farinelli S
FEMS Immunol Med Microbiol; 1993 Jun; 7(1):23-8. PubMed ID: 8364519
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric investigation of filamentation, membrane patency, and membrane potential in Escherichia coli following ciprofloxacin exposure.
Wickens HJ; Pinney RJ; Mason DJ; Gant VA
Antimicrob Agents Chemother; 2000 Mar; 44(3):682-7. PubMed ID: 10681338
[TBL] [Abstract][Full Text] [Related]
40. Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin.
Diver JM; Wise R
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():31-41. PubMed ID: 3542947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
